PreAcute PHM, Inc. is a Delaware “C” corp. involved in the business of facilitating proactive care of acute conditions (as opposed to the proactive care of chronic conditions that CMS currently patronizes) for the purpose of greater cost reduction by statistically lowering the no. of expensive treatments common for acute conditions, such as surgeries and dialysis. This affords improved commercial success under the Value Based Care, Shared Savings, and other similar reimbursement models. What’s NEW about our approaches, are: (1) Focusing on Acute Conditions – not targeted by the industry as yet; & (2) Focusing our interventions in the “preacute” stages of the diseases, before patients becomes “acutely ill.” In these stages, the patients are healthier and can respond more effectively to low-cost treatments. This effectively bends their health trajectories away from the path of expensive treatments and save on patient sufferings and cost. Proactive care is currently practiced only on patients with chronic conditions and that has been proven to be cost effective. However, the same has never been attempted for patients with acute conditions. Such patients are now customarily treated only after they reach certain exacerbated levels of illness and discomfort. Our approach is to identify them upstream, in the earlier stages of illnesses which, when left alone, ultimately lead to surgeries, dialysis, etc. We identify such patients in the earlier stages by use of our proprietary predictive model and then treat them according to a series of novel & proprietary clinical pathways to generate significant cost savings. Conventional clinical pathways are for acute stages of illnesses and may not be suitable for use in the pre-acute stages. That is why a whole new series of preacute clinical pathways had to be developed, adding significantly to the asset value of the company. The predictive model, and the data generated by the process of preacute treatments are other significant assets of the company. We are currently at a Startup Stage, beginning our Pilots. The performance data from the pilots will be used to calibrate the predictive model & clinical pathways, before launching into marketing phase in 2020